1. |
Trojanek J. Matrix metalloproteinases and their tissue inhibitors. Postepy Biochem, 2012, 58(3): 353-362.
|
2. |
Proveda VA, Casado HA, Gervantes RA,et al. Treatment guidelines in ovarian cancer. Clin Transl Oncol, 2007, 9(5): 308-316.
|
3. |
Howell A, Robertson JF, Abram P,et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer inpostmenopausal womenpreviously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol, 2004, 22(16): 5-13.
|
4. |
Fisher B, Costantino JP, Wickerham DL,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer inst, 1998, 90(18): 1371-1388.
|
5. |
Bardou VJ, Arpino G, Elledge RM,et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol, 2003, 21(10): 1973-1979.
|
6. |
Lee P, Rosen DG, Zhu C,et al. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol, 2005, 96(3): 671-677.
|
7. |
周支瑞, 张天崇, 李博, 等. 生存曲线中 Meta 分析适宜数据的提取与转换. 中国循证心血管医学杂志, 2014, 6(3): 243-247.
|
8. |
Wells GA, Shea B, O’connell D,et al. The Newcastle-Ottawa Scale (NOS) for assessing the guality if nonrandomized studies in meta-analysis [EB/OL]. 2015, 5: 26.
|
9. |
Lenhard M, Tereza L, Heublein S,et al. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer, 2012, 12: 553.
|
10. |
Kommoss F, Pfisterer J, Thome M,et al. Steroid Receptors in Ovarian Carcinoma: immunohistochemical Determination May Lead to New Aspects. Gynecol Oncol, 1992, 47(3): 317-322.
|
11. |
Scambia G, Benedetti-Panici P, Ferrandina G,et al. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer, 1995, 72(2): 361-366.
|
12. |
Lee P, Rosen DG, Zhu C,et al. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol, 2005, 96(3): 671-677.
|
13. |
García-Velasco A, Mendiola C, Sánchez-Muñoz A,et al. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol, 2008, 10(9): 367-371.
|
14. |
Yang XY, Xi MR, Yang K,et al. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients. Gynecol Oncol, 2009, 113(1): 99-104.
|
15. |
Buchynska LG, iurchenko NP, Grinkevych VM,et al. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian ancers. Exp Oncol, 2009, 31(1): 48-51.
|
16. |
Tangjitgamol S, Manusirivithaya S, Khunnarong J,et al. Expressions of Estrogen and Progesterone Receptors in Epithelial Ovarian Cancer: A Clinicopathologic Study. Int J Gynecol Cancer, 2009, 19(4): 620-627.
|
17. |
De Stefano I, Zannoni GF, Prisco MG,et al. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecol Oncol, 2011, 122(3): 573-579.
|
18. |
Battista MJ, Mantai N, Sicking I,et al. Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: Results of an explorative, retrospective study. Oncol Rep, 2014, 31(5): 2213-2219.
|
19. |
Tkalia IG, Vorobyova LI, Svintsitsky VS,et al. Clinical significance of hormonal receptor status of malignant ovarian tumors. Exp Oncol, 2014, 36(2): 125-133.
|
20. |
Jatoi A, Vierkant RA, Hawthorne KM,et al. Clinical and Emergent Biomarkers and Their Relationship to the Prognosis of ovarian Cancer. Oncology, 2015, 90(2): 59-68.
|
21. |
Jönsson JM, Skovbjerg AN, Malander Sr,et al. Sex steroid hormone receptor expression affects ovarian cancer surviva. Transl Oncol, 2015, 8(5): 424-433.
|
22. |
Harding M, Cowan S, Hole D,et al. Estrogen and progesterone receptor in ovarian cancer. Cancer, 1990, 65(3): 486-491.
|
23. |
Langdon SP, Gabra H, Bartlett JM. Functionality of the progester-one receptor in ovarian cancer and its regulation by estrogen. Clin Cancer Res, 1998, 4(9): 2245-2251.
|
24. |
Wu H, Wang K, Liu W,et al. PTEN overexpression improves cisplatin resistance of human ovarian cancer cells though upregulating KRT10 expression. Biochem Biophys Res Commun, 2014, 444(2): 141.
|
25. |
Geisler JP, Wiemann MC, Miller GA,et al. Estogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarinoma of the ovary. Gynecol Oncol, 1996, 60(3): 424-427.
|